268 related articles for article (PubMed ID: 21341745)
1. A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields.
Broccatelli F; Carosati E; Neri A; Frosini M; Goracci L; Oprea TI; Cruciani G
J Med Chem; 2011 Mar; 54(6):1740-51. PubMed ID: 21341745
[TBL] [Abstract][Full Text] [Related]
2. The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR).
Teodori E; Dei S; Martelli C; Scapecchi S; Gualtieri F
Curr Drug Targets; 2006 Jul; 7(7):893-909. PubMed ID: 16842220
[TBL] [Abstract][Full Text] [Related]
3. Lead identification for modulators of multidrug resistance based on in silico screening with a pharmacophoric feature model.
Langer T; Eder M; Hoffmann RD; Chiba P; Ecker GF
Arch Pharm (Weinheim); 2004 Jun; 337(6):317-27. PubMed ID: 15188221
[TBL] [Abstract][Full Text] [Related]
4. Computational models for identifying potential P-glycoprotein substrates and inhibitors.
Crivori P; Reinach B; Pezzetta D; Poggesi I
Mol Pharm; 2006; 3(1):33-44. PubMed ID: 16686367
[TBL] [Abstract][Full Text] [Related]
5. Shedding light on drug transport: structure and function of the P-glycoprotein multidrug transporter (ABCB1).
Sharom FJ
Biochem Cell Biol; 2006 Dec; 84(6):979-92. PubMed ID: 17215884
[TBL] [Abstract][Full Text] [Related]
6. The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter.
Ding PR; Tiwari AK; Ohnuma S; Lee JW; An X; Dai CL; Lu QS; Singh S; Yang DH; Talele TT; Ambudkar SV; Chen ZS
PLoS One; 2011 Apr; 6(4):e19329. PubMed ID: 21552528
[TBL] [Abstract][Full Text] [Related]
7. A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumors.
Kelly RJ; Robey RW; Chen CC; Draper D; Luchenko V; Barnett D; Oldham RK; Caluag Z; Frye AR; Steinberg SM; Fojo T; Bates SE
Oncologist; 2012; 17(4):512. PubMed ID: 22416063
[TBL] [Abstract][Full Text] [Related]
8. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.
Shukla S; Robey RW; Bates SE; Ambudkar SV
Drug Metab Dispos; 2009 Feb; 37(2):359-65. PubMed ID: 18971320
[TBL] [Abstract][Full Text] [Related]
9. Allosteric modulation of human P-glycoprotein. Inhibition of transport by preventing substrate translocation and dissociation.
Maki N; Hafkemeyer P; Dey S
J Biol Chem; 2003 May; 278(20):18132-9. PubMed ID: 12642584
[TBL] [Abstract][Full Text] [Related]
10. Cyclosporins: structure-activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC transporter.
Loor F; Tiberghien F; Wenandy T; Didier A; Traber R
J Med Chem; 2002 Oct; 45(21):4598-612. PubMed ID: 12361387
[TBL] [Abstract][Full Text] [Related]
11. Mini review on molecular modeling of P-glycoprotein (Pgp).
Ha SN; Hochman J; Sheridan RP
Curr Top Med Chem; 2007; 7(15):1525-9. PubMed ID: 17897039
[TBL] [Abstract][Full Text] [Related]
12. Prediction of promiscuous p-glycoprotein inhibition using a novel machine learning scheme.
Leong MK; Chen HB; Shih YH
PLoS One; 2012; 7(3):e33829. PubMed ID: 22439003
[TBL] [Abstract][Full Text] [Related]
13. Reconstitution and functional studies of hamster P-glycoprotein in giant liposomes.
Park S; Majd S
PLoS One; 2018; 13(6):e0199279. PubMed ID: 29912971
[TBL] [Abstract][Full Text] [Related]
14. Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier.
Nagasaka Y; Oda K; Iwatsubo T; Kawamura A; Usui T
Biopharm Drug Dispos; 2012 Sep; 33(6):304-15. PubMed ID: 22847220
[TBL] [Abstract][Full Text] [Related]
15. Methoxylation of 3',4'-aromatic side chains improves P-glycoprotein inhibitory and multidrug resistance reversal activities of 7,8-pyranocoumarin against cancer cells.
Fong WF; Shen XL; Globisch C; Wiese M; Chen GY; Zhu GY; Yu ZL; Tse AK; Hu YJ
Bioorg Med Chem; 2008 Apr; 16(7):3694-703. PubMed ID: 18313307
[TBL] [Abstract][Full Text] [Related]
16. Catalytic transitions in the human MDR1 P-glycoprotein drug binding sites.
Wise JG
Biochemistry; 2012 Jun; 51(25):5125-41. PubMed ID: 22647192
[TBL] [Abstract][Full Text] [Related]
17. PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanism.
Walter RB; Pirga JL; Cronk MR; Mayer S; Appelbaum FR; Banker DE
Blood; 2005 Nov; 106(10):3584-93. PubMed ID: 16051742
[TBL] [Abstract][Full Text] [Related]
18. Interaction field based and hologram based QSAR analysis of propafenone-type modulators of multidrug resistance.
Kaiser D; Smiesko M; Kopp S; Chiba P; Ecker GF
Med Chem; 2005 Sep; 1(5):431-44. PubMed ID: 16787327
[TBL] [Abstract][Full Text] [Related]
19. Identification of ligand-binding regions of P-glycoprotein by activated-pharmacophore photoaffinity labeling and matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry.
Ecker GF; Csaszar E; Kopp S; Plagens B; Holzer W; Ernst W; Chiba P
Mol Pharmacol; 2002 Mar; 61(3):637-48. PubMed ID: 11854445
[TBL] [Abstract][Full Text] [Related]
20. Computational models for prediction of interactions with ABC-transporters.
Ecker GF; Stockner T; Chiba P
Drug Discov Today; 2008 Apr; 13(7-8):311-7. PubMed ID: 18405843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
